Table 4.

Characteristics of key cost-effectiveness studies on CDI

Study	Chen et al.	Prabhu et al. [10]	Lam et al. [12]	Cornely et al. [9]
Model design	Markov transition	Markov transition	Decision tree	Markov transition
Time horizon	Lifetime	Lifetime	1 year	1 year
Perspective	Societal perspective	Payer’s perspective	Payer’s perspective	Health-care system perspective
Inclusion of indirect costs	Yes	No	No	No
Base case	Patients with any CDI episode	Patients with any CDI episode	Patients with first CDI recurrence	Patients with any CDI episode
Treatment arms	Vancomycin, Fidaxomicin, Bezlotoxumab + SOC, Extended-pulsed fidaxomicin	Bezlotoxumab + SOC, Placebo + SOC	Vancomycin, Fidaxomicin, Bezlotoxumab + SOC	Vancomycin, Extended-pulsed fidaxomicin
Most cost-effective treatment	Fidaxomicin	Bezlotoxumab + SOC	Vancomycin	Extended-pulsed fidaxomicin

Abbreviations: CDI, Clostridioides difficile infection; SOC, standard of care.